Cargando…

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients

BACKGROUND: The effect of palliative chemotherapy for non-small cell lung cancer (NSCLC) is well established. Recently, immune checkpoint inhibitors have shown promising efficacy in NSCLC patients. However, little is known about the efficacy of cytotoxic chemotherapy in patients whose tumors are ref...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rothschild, S.I., Nachbur, R., Herzog, N., Passweg, J.R., Pless, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809381/ https://www.ncbi.nlm.nih.gov/pubmed/33422767 http://dx.doi.org/10.1016/j.esmoop.2020.100013

Ejemplares similares

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
por: Felip, Enriqueta, et al.
Publicado: (2008)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)

TLR5 Variants Are Associated with the Risk for COPD and NSCLC Development, Better Overall Survival of the NSCLC Patients and Increased Chemosensitivity in the H1299 Cell Line
por: Baranašić, Jurica, et al.
Publicado: (2022)

Overall survival and second primary malignancies in men with metastatic prostate cancer
por: Mehtälä, Juha, et al.
Publicado: (2020)

Types of second primary cancer influence overall survival in cutaneous melanoma
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Clinical impact of post‐progression survival on overall survival in patients receiving nivolumab monotherapy as a second‐line treatment for advanced non‐small cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2021)

Overall Survival Prediction of Docetaxel-based Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
por: Nagaraju, Chaitra, et al.
Publicado: (2022)

Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer
por: Whitaker, Kristen D., et al.
Publicado: (2022)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients
por: Catarino, Raquel, et al.
Publicado: (2012)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC
por: Faoro, Lisa, et al.
Publicado: (2023)

Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
por: Qi, Wei-Xiang, et al.
Publicado: (2013)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
por: Shaw, A T, et al.
Publicado: (2019)

P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT
por: Kuter, D., et al.
Publicado: (2022)

Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with Lymph Node Status and Overall Survival
por: Botta, Francesca, et al.
Publicado: (2020)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab
por: Shang, Xiaoling, et al.
Publicado: (2021)

Survival after wedge resection versus lobectomy for stage IA second primary NSCLC with previous lung cancer-directed surgery
por: Song, Congkuan, et al.
Publicado: (2022)

Development and Validation of a Nomogram for Predicting Overall Survival in Patients with Second Primary Small Cell Lung Cancer After Non-Small Cell Lung Cancer: A SEER-Based Study
por: Zhu, Ju, et al.
Publicado: (2022)

The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non–Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy()()()
por: Yang, Ju, et al.
Publicado: (2017)

Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC
por: Kersting, David, et al.
Publicado: (2021)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
por: Ipek, Yildiz, et al.
Publicado: (2023)

Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis
por: Sun, Wenzheng, et al.
Publicado: (2018)

Increasing Heart Dose Reduces Overall Survival in Patients Undergoing Postoperative Radiation Therapy for NSCLC
por: Shepherd, Annemarie F., et al.
Publicado: (2021)

Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival
por: Wang, Zhaoxi, et al.
Publicado: (2015)

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
por: Gray, Jhanelle E., et al.
Publicado: (2019)

MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis
por: Dimou, Anastasios, et al.
Publicado: (2014)

Construction and Validation of Two Novel Nomograms for Predicting the Overall Survival and Cancer-Specific Survival of NSCLC Patients with Bone Metastasis
por: Dong, Qiu, et al.
Publicado: (2021)

Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience
por: Hagmann, Raphael, et al.
Publicado: (2015)

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
por: Crawford, Jeffrey, et al.
Publicado: (2019)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007)

Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data
por: Wang, Xuechen, et al.
Publicado: (2022)

Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients
por: Zhang, Na, et al.
Publicado: (2022)

Role of chemotherapy for survival in patients with second primary non‐small cell lung cancer
por: Wang, Zhile, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7ojsvumm62fujbscrn7ac9i0j4